CRSP - CRISPR Therapeutics AG


60
1.940   3.233%

Share volume: 1,170,589
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%

$58.06
1.94
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Income statement Balance sheet Cash flow To see more then 2 years history Buy Premium
View ratios

Fiscal Date 03-31-2024 06-30-2024 09-30-2024 12-31-2024 03-31-2025 06-30-2025 09-30-2025 12-31-2025
Fiscal Quarter Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Report Date 05-08-2024 08-05-2024 11-05-2024 02-11-2025 05-06-2025 08-04-2025 11-10-2025 02-12-2026
Total revenue 504.000 K 517.000 K 602.000 K 35.691 M 865.000 K 892.000 K 889.000 K 864.000 K
Cost of revenue 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Gross profit 504.000 K 517.000 K 602.000 K 35.691 M 865.000 K 892.000 K 889.000 K 864.000 K
    2.58% 16.44% 5,828.74% -97.58% 3.12% -0.34% -2.81%  
Operating expenses 94.125 M 99.646 M 99.579 M 100.280 M 91.780 M 185.063 M 75.833 M 101.925 M
Selling general and admin 17.953 M 19.481 M 17.419 M 18.124 M 19.296 M 18.916 M 16.931 M 18.399 M
Research and development 76.172 M 80.165 M 82.160 M 82.156 M 72.484 M 166.147 M 58.902 M 83.526 M
Total expenses 141.091 M 151.777 M 110.732 M 100.280 M 149.289 M 230.216 M 132.948 M 155.628 M
    7.57% -27.04% -9.44% 48.87% 54.21% -42.25% 17.06%  
Operating income -140.587 M -151.260 M -110.130 M -64.589 M -148.424 M -229.324 M -132.059 M -154.764 M
Ebit -115.867 M -125.121 M -85.066 M -36.611 M -134.887 M -207.257 M -105.822 M -129.999 M
Pretax income -115.867 M -125.121 M -85.066 M -36.611 M -134.887 M -207.257 M -105.822 M -129.999 M
    7.99% -32.01% -56.96% 268.43% 53.65% -48.94% 22.85%  
Income tax 724.000 K 1.287 M 876.000 K 700.000 K 1.109 M 1.292 M 619.000 K 614.000 K
Net income basic 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
                   
Net income -116.591 M -126.408 M -85.942 M -37.311 M -135.996 M -208.549 M -106.441 M -130.613 M
    -8.42% 32.01% 56.59% -264.49% -53.35% 48.96% -22.71%